De tre kliniske studier udført med Naglazyme fokuserede på at vurdere de systemiske manifestationer af MPS VI såsom udholdenhed, bevægelighed i led, ledsmerte og – stivhed, obstruktion af de øvre luftveje, manuel behændighed og synsskarphed.
The three clinical studies performed with Naglazyme focused on assessing the systemic manifestations of MPS VI such as endurance, joint mobility, joint pain and stiffness, upper airway obstruction, manual dexterity and visual acuity.